Monopar Therapeutics (MNPR) Change in Cash (2017 - 2025)

Monopar Therapeutics has disclosed Change in Cash across 9 years of filings, most recently posting -$65.8 million for Q4 2025.

• Change in Cash for Q4 2025 came in at -$65.8 million, down 265.45% year-over-year; the trailing twelve-month figure through Dec 2025 was $16.0 million (down 58.45% YoY), and the FY2025 annual result was $16.0 million, down 58.45% from the prior year.
• Change in Cash came in at -$65.8 million for Q4 2025 at Monopar Therapeutics, down from $88.2 million in the prior quarter.
• In the past five years, Change in Cash ranged from a high of $88.2 million in Q3 2025 to a low of -$65.8 million in Q4 2025.
• The 5-year median for Change in Cash is -$1.6 million (2021), against an average of $2.3 million.
• Across the five-year window, Change in Cash slumped 2997.62% in 2021 and surged 88410.54% in 2025, its largest moves.
• Monopar Therapeutics' Change in Cash stood at -$2.0 million in 2021, then plunged by 200.84% to -$6.1 million in 2022, then jumped by 128.56% to $1.8 million in 2023, then jumped by 2173.12% to $39.8 million in 2024, then plunged by 265.45% to -$65.8 million in 2025.
• The last three Change in Cash figures came in at -$65.8 million (Q4 2025), $88.2 million (Q3 2025), and -$209473.0 (Q2 2025), per Business Quant data.